

JOURNAL OF HEPATOLOGY

The Home of Liver Research

VOLUME 68, ISSUE 4, PAGES 631–868

FROM THE EDITOR'S DESK

From the Editor's desk

R. Moreau, R. Bataller, T. Berg, J. Zucman-Rossi and R. Jalan 631

EDITORIALS

Interfering with Kupffer cell replenishment: New insights into liver injury

W. Alazawi and P.A. Knolle 635

The Egyptian hepatitis C programme: A model of HCV treatment intervention?

M. Lemoine and G.S. Cooke 638

Non-alcoholic fatty liver disease: A risk factor for myocardial dysfunction?

C.D. Byrne and G. Perseghin 640

Pyroptosis: An inflammatory link between NAFLD and NASH with potential therapeutic implications

J.I. Beier and J.M. Banales 643

RESEARCH ARTICLES

Viral Hepatitis

The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen

H. Innes, S.T. Barclay, P.C. Hayes, A. Fraser, J.F. Dillon, A. Stanley, A. Bathgate, S.A. McDonald, D. Goldberg, H. Valerio, R. Fox, N. Kennedy, P. Bramley and S.J. Hutchinson 646

Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection

Z. Lei, Y. Xia, A. Si, K. Wang, J. Li, Z. Yan, T. Yang, D. Wu, X. Wan, W. Zhou, J. Liu, H. Wang, W. Cong, M. Wu, T.M. Pawlik, W.Y. Lau and F. Shen 655

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

P. Buggisch, J. Vermehren, S. Mauss, R. Günther, E. Schott, A. Pathil, K. Boeker, T. Zimmermann, G. Teuber, H.-P. Vornkahl, K.-G. Simon, C. Niederau, H. Wedemeyer and S. Zeuzem 663

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

K. Agarwal, M. Brunetto, W.K. Seto, Y.-S. Lim, S. Fung, P. Marcellin, S.H. Ahn, N. Izumi, W.-L. Chuang, H. Bae, M. Sharma, H.L.A. Janssen, C.Q. Pan, M.K. Çelen, N. Furusyo, Dr. Shalimar, K.T. Yoon, H. Trinh, J.F. Flaherty, A. Gaggar, A.H. Lau, A.L. Cathcart, L. Lin, N. Bhardwaj, V. Suri, G. Mani Subramanian, E.J. Gane, M. Buti, H.L.Y. Chan, GS-US-320-0110 and GS-US-320-0108 Investigators 672

Type I interferon receptor signaling delays Kupffer cell replenishment during acute fulminant viral hepatitis

K. Borst, T. Frenz, J. Spanier, P.-K. Tegtmeyer, C. Chhatbar, J. Skerra, L. Ghita, S. Namineni, S. Lienenklaus, M. Köster, M. Heikenwaelder, G. Sutter and U. Kalinke 682

Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience

A. Elsharkawy, M. El-Raziky, W. El-Akel, K. El-Saeed, R. Eletreby, M. Hassany, M.H. El-Sayed, K. Kabil, S.A. Ismail, M. El-Serafy, A.O. Abdelaziz, M.K. Shaker, A. Yosry, W. Doss, Y. El-Shazly, G. Esmat and I. Waked 691

Transplantation

Impact of real-time metabolomics in liver transplantation: Graft evaluation and donor-recipient matching

F. Faitot, C. Besch, S. Battini, E. Ruhland, M. Onea, P. Addeo, M.-L. Woehl-Jaeglé, B. Ellero, P. Bachellier and I.-J. Namer 699

A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort

J.L.A. van Vugt, L.J.M. Alferink, S. Buettner, M.P. Gaspersz, D. Bot, S. Darwish Murad, S. Feshtali, P.M.A. van Ooijen, W.G. Polak, R.J. Porte, B. van Hoek, A.P. van den Berg, H.J. Metselaar and J.N.M. IJzermans 707

Cancer

Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm

M. Ronot, O. Fouque, M. Esvan, J. Lebigot, C. Aubé and V. Vilgrain 715

Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion

C. Spreafico, C. Sposito, M. Vaiani, T. Cascella, S. Bhoori, C. Morosi, R. Lanocita, R. Romito, C. Chiesa, M. Maccauro, A. Marchianò and V. Mazzaferro 724

Molecular and Cell Biology

Macrophage scavenger receptor 1 contributes to pathogenesis of fulminant hepatitis via neutrophil-mediated complement activation

Y. Tang, H. Li, J. Li, Y. Liu, Y. Li, J. Zhou, J. Zhou, X. Lu, W. Zhao, J. Hou, X.-Y. Wang, Z. Chen and D. Zuo 733

Adult hepatocytes direct liver organogenesis through non-parenchymal cell recruitment in the kidney

R. Utoh, J. Komori, H. Kuge, K. Tatsumi, M. Yamada, S. Hirohashi, M. Tsutsumi, T. Amanuma, A. Yoshioka, Y. Nakajima, K. Wake, T. Okano, E. Lagasse and K. Ohashi 744

Cholestasis and Autoimmune Diseases

Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis

J. Hartl, H. Ehken, M. Sebode, M. Peiseler, T. Krech, R. Zenouzi, J. von Felden, C. Weiler-Normann, C. Schramm and A.W. Lohse 754

Genetic and Metabolic Diseases

Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients

Y.-h. Lee, K.J. Kim, M.e. Yoo, G. Kim, H.-j. Yoon, K. Jo, J.-C. Youn, M. Yun, J.Y. Park, C.Y. Shim, B.-W. Lee, S.-M. Kang, J.-W. Ha, B.-S. Cha and E.S. Kang 764

Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice

B. Xu, M. Jiang, Y. Chu, W. Wang, D. Chen, X. Li, Z. Zhang, D. Zhang, D. Fan, Y. Nie, F. Shao, K. Wu and J. Liang 773

REVIEWS

Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations

J.-C. Nault, O. Sutter, P. Nahon, N. Ganne-Carrié and O. Séror 783

Potentially inappropriate liver transplantation in the era of the “sickest first” policy – A search for the upper limits

M. Linecker, T. Krones, T. Berg, C.U. Niemann, R.H. Steadman, P. Dutkowski, P.-A. Clavien, R.W. Busuttill, R.D. Truog and H. Petrowsky 798

Eliminating hepatitis C within low-income countries – The need to cure genotypes 4, 5, 6

T. Asselah, T. Hassanein, I. Waked, A. Mansouri, G. Dusheiko and E. Gane 814

SPECIAL SECTIONS

Grand Rounds

Clinical management of polycystic liver disease

R.M.M. van Aerts, L.F.M. van de Laarschot, J.M. Banales and J.P.H. Drenth 827

Hepatology Snapshot

Hepatic encephalopathy: Classification and treatment

J.S. Bajaj 838

LETTERS TO THE EDITOR

Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial

A.L.H. Øvrehus, H. Krarup, I. Birkemose, D.K. Holm, B. Mössner, A. Ernst and P.B. Christensen 840

Acute liver failure: Do the EASL guidelines address the whole spectrum?

M. Mendizabal and M. Silva 843

Direct antiviral agents against hepatitis C virus: Beneficial or harmful?

Ó. Murcia, F. Carnicer, L. Gómez-Escolar, C. Miralles, M.P. Griñó, C. Barquero Martín and S. Pascual 844

The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients

M.P. Carrieri, C. Protopopescu, F. Marcellin, L. Wittkop, K. Lacombe, L. Esterle, P. Sogni, D. Salmon-Ceron and ANRS CO13 HEPAVIH Study Group 845

HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient

J. Wang, Q. Sheng, Y. Ding, R. Chen, X. Sun, X. Chen, X. Dou and F. Lu 847

Reply to: “HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient”

J. Wang, Y. Yu, Z. Meng, C. Shen, M. Zhang, P. Qian, C. Zhao, X. Wang, Y. Huang, J. Zhang, C. Qiu and W. Zhang 849

Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?

K.L. Hupa, K. Deterding, K. Port, M. Kimmann, M.P. Manns, H. Wedemeyer and M. Cornberg 851

Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?

Y. Nakao, S. Hashimoto, S. Abiru, A. Komori, K. Yamasaki, S. Nagaoka, A. Saeki, S. Bekki, Y. Kugiyama, T. Kuroki, M. Ito, K. Nakao and H. Yatsushiro
854

Energy drinks and adolescents – A hepatic health hazard?

S. Robin, R. Buchanan and R. Poole
856

Reply to: “Energy drinks and adolescents – A hepatic health hazard?”

V. Nobili, A. Mosca, E. Scorletti and C.D. Byrne
857

The *PNPLA3* SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort

P.J. Meffert, K.D. Repp, H. Völzke, F.U. Weiss, G. Homuth, J.P. Kühn, M.M. Lerch and A.A. Aghdassi
858

Reply to: “The *PNPLA3* SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort”

S.R. Atkinson, M.J. Way, A. McQuillin, M.Y. Morgan and M.R. Thursz
860

Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea?

T.-I. Huo, P.-H. Liu and C.-Y. Hsu
862

Reply to: “Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea?”

S. Lee and S.H. Kim
863

Reply to: “Reply to: ‘Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries’”

A. da Silva Filipe, V. Sreenu, J. Hughes, E. Aranday-Cortes, W.L. Irving, G.R. Foster, K. Agarwal, W. Rosenberg, D. Macdonald, P. Richardson, M.A. Aldersley, M. Wiselka, A. Ustianowski, J. McLauchlan and E.C. Thomson
864

CORRIGENDUM

Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41]

A. Karampatou, X. Han, L.A. Kondili, G. Taliani, A. Ciancio, F. Morisco, R.M. Critelli, E. Baraldi, V. Bernabucci, G. Troshina, M. Guarino, S. Tagliavini, F. D’Ambrosio, L. Bristot, L. Turco, S. Rosato, S. Vella, T. Trenti, I. Neri, A. La Marca, S. Manthena, A.S. Goldstein, S. Bruno, Y. Bao, Y.S. Gonzalez, E. Villa and PITER framework investigators
867

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

Cover image: Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice, by B. Xu *et al.* on pp. 773–782 in this issue.

A moment in time: Gasdermin D cleavage. Cover design by Caitlin Monney.